Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts.
about
Nitrates for the prevention of cardiac morbidity and mortality in patients undergoing non-cardiac surgeryA friend within the heart: natriuretic peptide receptor signalingSildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin TNitrates for the prevention of cardiac morbidity and mortality in patients undergoing non-cardiac surgeryBreakthrough in heart failure with preserved ejection fraction: are we there yet?Interaction of Hydrogen Sulfide with Nitric Oxide in the Cardiovascular SystemNatriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic EventsInhibition of DNA synthesis in cultured hepatocytes by endotoxin-conditioned medium of activated stellate cells is transforming growth factor-beta and nitric oxide-independentPressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient miceStatins as antioxidant therapy for preventing cardiac myocyte hypertrophyComparative cardiac toxicity of anthracyclines in vitro and in vivo in the mouseActivated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivoCyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heartMyomaxin is a novel transcriptional target of MEF2A that encodes a Xin-related alpha-actinin-interacting proteinEndothelial dysfunction is associated with left ventricular mass (assessed using MRI) in an adult population (MESA).Role of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts.Elevation of intracellular calcium levels contributes to the inhibition of nitric oxide production by atrial natriuretic peptide.A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions.Natriuretic Peptide Signaling via Guanylyl Cyclase (GC)-A: An Endogenous Protective Mechanism of the Heart.Astragalus polysaccharide ameliorates H2O2-induced human umbilical vein endothelial cell injury.Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibitionKMUP-1 attenuates isoprenaline-induced cardiac hypertrophy in rats through NO/cGMP/PKG and ERK1/2/calcineurin A pathwaysOxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load.Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes.Heart failure with preserved ejection fraction: molecular pathways of the aging myocardiumInhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes.Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt.Guanylyl cyclase/natriuretic peptide receptor-A signaling antagonizes phosphoinositide hydrolysis, Ca(2+) release, and activation of protein kinase CThe natriuretic peptides: physiology and role in left-ventricular dysfunction.Cardiac natriuretic peptides--hope or hype?cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.Salt-sensitive hypertension and cardiac hypertrophy in transgenic mice expressing a corin variant identified in blacksRegulation of apoptosis by vasoactive peptides.Protein kinase G I and heart failure: Shifting focus from vascular unloading to direct myocardial antiremodeling effects.Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload.Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycinCorin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activityReceptor crosstalk. Implications for cardiovascular function, disease and therapy.Nuclear targeting of Akt antagonizes aspects of cardiomyocyte hypertrophy.Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity.
P2860
Q24200669-BFC52AFC-B681-40CD-B124-22D1897B5FC7Q24300973-8030660A-C7F4-4123-918B-EFCC8023E35BQ24805251-32C30932-A3D4-41C1-BCEC-11CA087D04B9Q26470504-BE7BA0FD-8405-43DB-8CBA-7DAB75F52D3DQ26771999-9E367722-A265-490A-A74A-A44C2498660CQ26774063-0AE28697-06B8-494C-8B1F-C5F5C9E8D19CQ26778333-15C86DA3-B41F-41A3-A454-5BB84BF836ABQ28345482-A3191304-E2EA-45DF-ABA2-0CC2B4A274DCQ28362795-B706DA9C-898C-4FAE-A4B4-D32FD3C1E904Q28364452-E0AF8D47-813F-4810-B770-00B00CC5CCC4Q28487998-6B2FA195-4335-425E-9F95-BD3E83A95F90Q28511213-6CD1C4AA-9061-4605-AE9A-6DF1FA06A61BQ28574432-58F9BD61-48AD-4694-8EFC-1DCB2EABAE75Q28585105-71E7DC04-2D24-465D-A4B8-3A530D9088DCQ30429138-5387D794-1CEB-483B-BBA2-AE8815255C84Q30575578-D40C8E72-9D3C-4EA8-A78D-BDC3379955E0Q31901092-A82B181C-5E72-4463-B07F-BAF2BA6E725AQ33577067-45650735-51E0-4E50-80C5-7D99C11907DCQ33578038-74D6FB91-C40C-4606-AEFF-84D34AB3F6ABQ33702185-645F5EE7-3AD9-4203-B32E-BC3771368C51Q33724430-BF4128B9-8EF3-4F84-B732-CC0411C7DB7DQ33730630-1259475E-2994-4B5F-97FD-1462A2DFA644Q33743649-BCCA2D0C-E736-4290-96F4-1B263148D2EBQ33777629-E60F0197-1475-4CCA-B5D9-A1DC65EC48C9Q33889242-0C8F059D-8041-4741-A7CF-8F088DD07E99Q34038333-B49EDB9B-3563-41D3-8D2A-5B91C77F84F2Q34048466-88924DFD-64BA-407C-AC66-D3B197C32F87Q34076973-4BDEF38D-EF24-4FC4-A22D-DAEAABA1C414Q34171357-0EDECC3C-ECE2-4BC0-8DE8-22D3B3CC302FQ34207401-85064964-C5A8-4405-9ACC-154108249812Q34244951-C8FBEB7D-9764-4D93-97A6-3DB3D21F7B61Q34300359-B9826200-22AE-4A10-B6EA-E884FD3A5FEDQ34369962-61E9FEC3-3F20-4744-AFCB-C01E7BA8D797Q34421211-DDAC4CD4-AEB0-4DF6-B4F8-538DAB71A215Q34498911-61E3B6AB-0716-4085-8705-F60FE863B3E3Q34627013-C840EB43-D1BB-49F6-A770-E92997329CE0Q34803094-91A452A8-C3AB-4AC4-9094-A6D6D3B7109EQ34920635-2F1A398E-69CB-47F1-910A-26694AB7B153Q35033113-79334FC2-2915-4153-BD59-4C550DCF1CAAQ35035923-1868665D-08F8-4B16-9509-A99D6E1BCBA0
P2860
Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Nitric oxide, atrial natriuret ...... diac myocytes and fibroblasts.
@en
Nitric oxide, atrial natriuret ...... diac myocytes and fibroblasts.
@nl
type
label
Nitric oxide, atrial natriuret ...... diac myocytes and fibroblasts.
@en
Nitric oxide, atrial natriuret ...... diac myocytes and fibroblasts.
@nl
prefLabel
Nitric oxide, atrial natriuret ...... diac myocytes and fibroblasts.
@en
Nitric oxide, atrial natriuret ...... diac myocytes and fibroblasts.
@nl
P2093
P2860
P356
P1476
Nitric oxide, atrial natriuret ...... diac myocytes and fibroblasts.
@en
P2093
P2860
P304
P356
10.1172/JCI119883
P407
P577
1998-02-01T00:00:00Z